Physician profile
Sheryl V Thacker
NPI 1053454389
$6,939.05
in general payments reported to CMS, 2019-2025
44 companies · $1,105 in 2025
The $1,105 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,405 · 2020: $809 · 2021: $830 · 2022: $638 · 2023: $1,089 · 2024: $1,062 · 2025: $1,105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,242 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,242.25 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $787.08 | 2019-2025 | Cabenuva, Apretude, Rukobia |
| Gilead Sciences, INC. | $690.05 | 2019-2025 | |
| Lilly USA, LLC | $646.55 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $643.84 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Merz North America, INC. | $442.30 | 2019 | |
| Merck Sharp & Dohme LLC | $387.80 | 2019-2025 | Delstrigo, Pifeltro, Dificid |
| Amgen INC. | $365.46 | 2019-2025 | Evenity, Prolia |
| Janssen Biotech, INC. | $327.82 | 2019-2023 | Symtuza |
| Abbvie INC. | $308.59 | 2019-2025 | Ubrelvy |
| Theratechnologies INC. | $285.50 | 2019-2025 | Egrifta, Trogarzo |
| Napo Pharmaceuticals INC | $185.02 | 2019-2025 | Mytesi |
| Esperion Therapeutics, INC. | $180.15 | 2021-2025 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $148.21 | 2019-2024 | Airsupra |
| Allergan, INC. | $109.47 | 2019-2020 | |
| Pfizer INC. | $107.29 | 2019-2024 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $104.14 | 2019-2022 | |
| Glaxosmithkline, LLC. | $95.19 | 2020-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $91.32 | 2019-2020 | |
| Astellas Pharma US INC | $76.03 | 2023-2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $66.99 | 2019-2022 | |
| Tolmar, INC. | $64.55 | 2023-2025 | Jatenzo |
| Dexcom, INC. | $60.44 | 2021-2025 | Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $57.74 | 2021-2022 | |
| Exact Sciences Corporation | $52.81 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Abbott Laboratories | $52.21 | 2022-2025 | Freestyle Libre 3 |
| Hologic Sales and Service, LLC | $49.17 | 2019-2023 | Aptima |
| Madrigal Pharmaceuticals | $48.32 | 2025 | Rezdiffra |
| Amarin Pharma, INC. | $47.02 | 2019-2020 | |
| Acerus Pharmaceuticals Corporation | $44.62 | 2022-2023 | Natesto |
| Paratek Pharmaceuticals, INC. | $44.01 | 2023 | Nuzyra |
| Idorsia Pharmaceuticals US INC | $40.62 | 2022-2023 | Quviviq |
| Ultragenyx Pharmaceutical INC. | $39.38 | 2019-2023 | |
| Sanofi Pasteur INC. | $34.75 | 2019-2023 | |
| Radius Health, INC. | $32.82 | 2025 | Tymlos |
| Novartis Pharmaceuticals Corporation | $32.46 | 2025 | |
| Medtronic, INC. | $31.59 | 2024 | Minimed 780g |
| Lundbeck LLC | $30.44 | 2024 | Rexulti |
| Tandem Diabetes Care, INC. | $24.98 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Insulet Corporation | $23.84 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.14 | 2025 | Jardiance |
| Sequel Med Tech, LLC | $17.02 | 2025 | Twiist |
| Philips North America LLC | $16.22 | 2024 | (Ck7) Extended Holter |
| Ethicon US, LLC | $15.35 | 2022 | |
| Emd Serono, INC. | $12.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheryl Thacker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.